Health
CHOP researchers identify key target responsible for treatment failure in patients with hemophilia A – News-Medical.Net
Researchers at Children’s Hospital of Philadelphia have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia…
Researchers at Children’s Hospital of Philadelphia (CHOP) have identified a key target that may be responsible for treatment failure in about 30% of patients with hemophilia A. The target, known as B cell activating factor (BAFF), appears to promote antibodies against and inhibitors of the missing blood clotting factor that is given to these patients to control their bleeding episodes. The findings, published in the Journal of Clinical Investigation, raise the possibility of using anti-BAFF therapies,…
-
Business22 hours ago10 high-conviction ASX dividend shares to buy for passive income today
-
Noosa News24 hours agoFarmers call for policy reform across multiple sectors as productivity collapses
-
Noosa News19 hours agoHuge suburban crowd cheers for luxury house sale at sausage sizzle auction
-
Noosa News20 hours agoTrump’s trade war puts Australian beef centre stage in Shanghai